Applied Evidence

Is diabetes distress on your radar screen?

Author and Disclosure Information

 

References

Problem Areas in Diabetes (PAID): There are 3 versions of PAID—a 20-item screen assessing a broad range of feelings related to living with diabetes and its treatment, a 5-item version (PAID-5) with high rates of sensitivity (95%) and specificity (89%), and a single-item test (PAID-1) that is highly correlated with the longer version.26,27

Diabetes Distress Scale (DDS): This tool is available in a 17-item measure assessing diabetes distress as it relates to the emotional burden, physician-related distress, regimen-related distress, and interpersonal distress.28 DDS is also available in a short form (DDS-2) with 2 items29 and a 28-item scale specifically for patients with type 1 diabetes.30 T1-DDS, the only diabetes distress measure focused on this particular patient population, assesses the 7 sources of distress found to be common among adults with type 1 diabetes: powerlessness, negative social perceptions, physician distress, friend/family distress, hypoglycemia distress, management distress, and eating distress.

Studies have shown that not only do those with type 1 diabetes experience different stressors compared with their type 2 counterparts, but that they tend to experience distress differently. For patients with type 1 diabetes, for example, powerlessness ranked as the highest source of distress, followed by eating distress and hypoglycemia distress. These sources of distress differ from the regimen distress, emotional burden, interpersonal distress, and physician distress identified by those with type 2 diabetes.30

How to respond to diabetes distress

Diabetes distress is easier to identify than to successfully treat. Few validated treatments for diabetes distress exist and, to our knowledge, only 2 studies have assessed interventions aimed at reduction of such distress.31,32

The REDEEM trial31 recruited adults with type 2 diabetes and diabetes distress to participate in a 12-month randomized controlled trial (RCT). The trial had 3 arms, comparing the effectiveness of a computer-assisted self-management (CASM) program alone, a CASM program plus in-person diabetes distress-specific problem-solving therapy, and a computer-assisted minimally supportive intervention. The main outcomes included diabetes distress (using the DDS scale and subscales), along with self-management behaviors and HbA1c.

Participants in all 3 arms showed significant reductions in total diabetes distress and improvements in self-management behaviors, with no significant differences among the groups. No differences in HbA1c were found. However, those in the CASM program plus distress-specific therapy arm showed a larger reduction in regimen distress compared with the other 2 groups.31

The DIAMOS trial32 recruited adults who had type 1 or type 2 diabetes, diabetes distress, and subclinical depressive symptoms for a 2-arm RCT. One group underwent cognitive behavioral interventions, while the controls had standard group-based diabetes education. The main outcomes included diabetes distress (measured via the PAID scale), depressive symptoms, well-being, diabetes self-care, diabetes acceptance, satisfaction with diabetes treatment, HbA1c, and subclinical inflammation.

Major depressive disorder, anxiety disorders, and diabetes distress are all common in patients with diabetes.

The intervention group showed greater improvement in diabetes distress and depressive symptoms compared with the control group, but no differences in well-being, self-care, treatment satisfaction, HbA1c, or subclinical inflammation were observed.32

Pages

Recommended Reading

Examining the safety of lipid-lowering drugs in pregnancy
MDedge Family Medicine
New guidelines provide standardized hypoglycemia values for clinical evaluation
MDedge Family Medicine
Empagliflozin first antidiabetes drug to gain cardioprotective indication
MDedge Family Medicine
Diabetes treatment costs doubled in Sweden since 2006
MDedge Family Medicine
Landmark psychosocial guidelines for diabetes spark debate over the ideal vs. the practical
MDedge Family Medicine
FDA affirms bladder cancer warning with diabetes drug
MDedge Family Medicine
XR version of Synjardy gets FDA’s nod
MDedge Family Medicine
FDA expands indication for continuous glucose monitoring system
MDedge Family Medicine
ADA: Empagliflozin and liraglutide reduce type 2 CV death
MDedge Family Medicine
Diabetes, ischemic heart disease, pain lead health spending
MDedge Family Medicine